GAVI negotiates HPV vaccine prices for developing countries
This article was originally published in Scrip
Executive Summary
The GAVI Alliance has announced it is to fund vaccines against the human papillomavirus (HPV) and negotiations with the companies that market vaccines, GlaxoSmithKline and Merck & Co, are underway, said a GAVI spokesperson. The public-private vaccination initiative says it must secure a "sustainable price" from manufacturers. It is unclear what this price might be, but will likely be below $5 per dose.